From the desk of Thomas Bruni @BruniCharting
During broad rallies in the equity markets, both in the US and globally, I look for those names / sectors / indices that are not participating to the upside, as those are normally the ones that lead to the downside once the market moves lower. One of the names that caught my eye during the rally off the February lows is Pfizer.
Before getting into the analysis of Pfizer, I think it’s important to point out the weak relative performance of the sector it belongs to.
The roughly 5 year daily chart of the ratio XLV / SPY shows the under-performance that’s been occurring in Healthcare stocks relative to the S&P 500 since mid-2015. Recently this ratio broke down below its primary uptrend line from the 2012 lows while momentum remains in a bearish range, suggesting that this under-performance is likely to continue.